KEGG   DRUG: Dolutegravir and lamivudine
Entry
D11522            Mixture   Drug                                   

Name
Dolutegravir and lamivudine;
Dovato (TN)
Product
Component
(Dolutegravir sodium [DR:D10113] | Dolutegravir [DR:D10066]), Lamivudine [DR:D00353]
Remark
Therapeutic category: 6250
ATC code: J05AR25
Product: D11522<JP/US>
Efficacy
Antiviral
  Disease
HIV-1 infection [DS:H01563]
Comment
Dolutegravir is metabolized by UGT1A1 with some contribution from CYP3A; it is also an inhibitor of OCT2 and MATE1.
Target
HIV-1 integrase
RNA-directed DNA polymerase
Metabolism
Enzyme: CYP3A [HSA:1576 1577 1551], UGT1A1 [HSA:54658]
Interaction
Transporter inhibition: SLC22A2 [HSA:6582], SLC47A1 [hsa:55244]
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J05 ANTIVIRALS FOR SYSTEMIC USE
   J05A DIRECT ACTING ANTIVIRALS
    J05AR Antivirals for treatment of HIV infections, combinations
     J05AR25 Lamivudine and dolutegravir
      D11522  Dolutegravir and lamivudine <JP/US>
USP drug classification [BR:br08302]
 Antivirals
  Anti-HIV Combinations
   Dolutegravir/ Lamivudine
    D11522  Dolutegravir and lamivudine
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D11522  Dolutegravir and lamivudine
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11522
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D11522
 Drug transporters
  D11522
Other DBs
PubChem: 384585498

» Japanese version   » Back

DBGET integrated database retrieval system